Phase 1 COPD Trial, Recruiting NCT07267130 Sponsor: Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd. Condition: COPD
Back to Copd

Phase 1 COPD Trial, Recruiting

NCT07267130
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are willing to join voluntarily and sign a consent form after being fully informed about the study
  • Healthy adults between 18 and 55 years old (inclusive), of any gender
  • Men who weigh at least 50kg and women who weigh at least 45kg, with a body mass index (BMI) between 19 and 28 kg/m²
  • People who pass a training assessment on how to use an inhaler correctly
  • People whose lung function tests during screening show healthy breathing levels (at least 80% of the expected value for a standard breathing test, and a normal ratio between two breathing measurements) (confirm with trial site)
  • People who have no plans to become pregnant and who agree to use effective contraception from the time of screening until at least 90 days after the last dose — this applies to participants and their partners

Who may not be able to join:

  • People with a history of glaucoma, chronic constipation, an enlarged prostate, urinary blockage, or similar conditions
  • People with a current history of active tuberculosis, bronchiectasis, or other long-term lung conditions
  • People who have received or are planning to receive any vaccine (including flu shots or other routine vaccines) in the 30 days before screening or at any point during the study
  • People with a history of drug allergies, or any significant pattern of allergic reactions
  • People who had surgery in the month before screening, or who expect to have surgery during the study period
  • People with special dietary needs that would prevent them from following a standard meal plan during the study
  • People who have difficulty with blood draws, or who have a history of fainting or feeling unwell around needles or blood
  • People with a history of drug or narcotics misuse, or whose urine drug test at screening comes back positive
  • People whose screening results for vital signs, physical examination, blood tests, chest X-ray, or abdominal ultrasound show abnormal results considered clinically significant
  • People who test positive for Hepatitis B, Hepatitis C, HIV, or syphilis
  • Women who are pregnant or breastfeeding, or whose blood pregnancy test at screening comes back positive

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 15300059186

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd.
Registry
ClinicalTrials.gov
Start date
25 November 2025
Est. completion
1 October 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Treatment Emergent Adverse Event; The subject with abnormal security check

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov